Table 1.

Demographic and clinicopathologic characteristics of melanoma patients treated with immunotherapy

Variable	Number of patients (n = 71)
Age at diagnosis (years)
Median (Range)	55 (21–80)
Gender
Male	40 (56.3%)
Female	31 (43.7%)
AJCC stage at diagnosis
I	5 (7.1%)
II	26 (36.6%)
III	40 (56.3%)
Primary TILs
Absent	16 (22.6%)
Present	52 (73.2%)
Non-brisk	29
Brisk	23
Unclassified	3 (4.2%)
Immunotherapy setting a
Adjuvant	40 (56.3%)
At Recurrence	31 (43.7%)
Type of immunotherapy
Immune biologic	38 (53.5%)
IFN-α	21
IL-2, IL-18	4
GM-CSF	12
Other	1
Vaccine	33 (46.5%)
Dendritic cell	11
Peptide	22

Abbreviations: AJCC American joint committee on cancer, TILs Tumor-infiltrating lymphocytes, NOS Not otherwise specified.

^aPatients who received immunotherapy in both settings (n=6).